65,437 trials
Lewy Body Disease · Lewy Body Variant of Alzheimer Disease · Lewy Body Dementia With Behavioral Disturbance
Primary: Dementia Cognitive Fluctuations Scale — 11.75; 8.33 score on a scale — p=<0.001
ALL, Childhood · Lymphoblastic Leukemia, Acute, Childhood · Lymphoblastic Leukemia, Acute
Primary: Number of Participants With Dose Limiting Toxicities as a Measure of Safety and Tolerability — 0; 2; 0; 1 Participants
Cardiovascular Surgery · Pain, Postoperative · Block
Primary: Total Postoperative Opioid Measured in Milligram Morphine Equivalent (MME) at 72 Hours — 29.4; 25.8 Milligram Morphine Equivalent (MME)
Diet Habit · Sugar-Sweetened Beverages
Primary: Change From Baseline Sugar-sweetened Beverage Fluid Milliters/Day at 9-weeks — -897.0; -291.0 fluid milliters/day
Tobacco Smoking
Primary: Cotinine-verified 7-day Smoking Abstinence at 12 Weeks — 3; 4 Participants — p=0.71
Pulmonary Disease, Chronic Obstructive
Primary: Change in Exercise Time (Seconds) During Cycle Ergometer Exercise. — 382.50; 328 seconds
Fabry's Disease
Primary: Percent Reduction in Shortest Tolerated Infusion Duration From Pre-study Average of Recent 3 Infusions — 84.19 percent
Chronic Hepatitis C Virus · Hepatitis C, Chronic · Hepatitis C
Primary: Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12) — 210 Participants
Dry Eye
Primary: Mean Change From Baseline (CFB) in Dry Eye Symptom Severity at Visit 3 — -44.5 score on a scale
Anxiety · Depression · Adolescent Behavior
Primary: Feasibility - IP Use Proportion — 0.10; 0.11; 0.10; 0.08 average proportion
Mild Cognitive Impairment · Cognitive Impairment · Alzheimer Disease
Primary: Number of Participants With Treatment-Related Serious Adverse Events as Assessed by CTCAE v5.0 — 0; 0; 0; 0 participants
Pulmonary Arterial Hypertension
Primary: Fold Change From Baseline at Week 24 in Pulmonary Vascular Resistance Index (PVRI) — 59.43 Fold change (percentage)
Asthma Childhood
Primary: Percentage of Participants With 1 or More Guideline-based Corrective Actions Taken — 241; 197 Participants — p=<.001
Advanced Solid Tumor
Primary: Frequency of Treatment-Related Adverse Event of CTCAE Grade 3 and Above — 2; 5; 6; 2 Participants
Complex Insomnia
Primary: Change in Pittsburgh Sleep Quality Index (PSQI) (32) at 6 Months Post-randomization — -5.25; -5.45 units on a scale — p=0.05